I'm LongbridgeAI, I can summarize articles.Puma Biotechnology reported a 38.98% year-over-year increase in Q2 FY26 GAAP net income to $8.2 million, with revenue rising 7.82% to $56.5 million. The company raised its full-year 2026 outlook for net product revenue to $205-209 million and net income to $17-20 million. CEO Alan H. Auerbach highlighted growing demand for NERLYNX and noted that ALISCA-Lung2 enrollment is targeted for Q3 2026.
- Puma Biotechnology posted GAAP net income of USD 8.2 million in Q2 2026, up 38.98% year over year. * Total revenue rose 7.82% to USD 56.5 million, led by net product revenue of USD 53.6 million; royalty revenue was USD 2.9 million. * Operating costs and expenses increased 6.77% to USD 48.9 million, reflecting higher R&D spend of USD 18.9 million. * Raised full-year 2026 outlook for net product revenue to USD 205-209 million; net income lifted to USD 17-20 million. * CEO Alan H. Auerbach cited rising demand for NERLYNX, with ALISCA-Lung2 enrollment initiation targeted for Q3 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608061605BIZWIRE_USPR_____20260806_BW108241) on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)